Merck/Schering-Plough Backpedals on Vytorin Trial Endpoint

A U-turn by Merck/Schering-Plough Pharmaceuticals over the primary endpoint of a controversial trial with the joint venture’s combination cholesterol management drug Vytorin/Inegy (simvastatin + ezetimibe) has done little to quell speculation over potential data manipulation in the ENHANCE study — or, indeed, over whether Vytorin offers any real clinical benefit compared with statin monotherapy.
PharmaTimes